Fexapotide

Summary

Fexapotide (CHEMBL3545061) is a phase-3 clinical-stage protein (ATC G04CX04); indicated across 1 condition including benign prostatic hyperplasia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• ATC class: G04CX04
• Indications: 1 condition
• Clinical trials: 7
• Chemistry: 2055.5 Da · C90H163N27O25S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545061
Name	Fexapotide
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	16207730
ATC	G04CX04
Molecular formula	C90H163N27O25S
Molecular weight	2055.5
InChIKey	BROGCIMRGWLMOO-SJPGHYFNSA-N

SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)N

IUPAC name: (2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoic acid

Also known as: Fexapotida, Fexapotide, NX-1207, NYM-4805, NYM4805, FEXAPOTIDE

Parent form; salt/anhydrous children: CHEMBL3707309

Patent coverage: 11 distinct patent families (28 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
benign prostatic hyperplasia	3	MONDO:0010811	EFO:0000284

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00918983	PHASE3	COMPLETED	Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
NCT00945490	PHASE3	COMPLETED	Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
NCT01438775	PHASE3	COMPLETED	Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
NCT01846793	PHASE3	COMPLETED	Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
NCT02003742	PHASE3	TERMINATED	Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH
NCT00759135	PHASE2	COMPLETED	Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
NCT01620515	PHASE2	COMPLETED	Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).